Compare ARK Genomic Revolution ETF (ARKG) vs Braze Inc (BRZE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Braze Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Braze Inc trades at $25.28 (market cap $2.83B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | BRZE | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $36.19 |
52-Week Low | $23.09 | $15.79 |
Market Cap | — | $2.83B |
Enterprise Value | — | $2.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Braze (BRZE) trades at $25.13, up 1.17% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth, reaching $593.41M in 2025, but remains unprofitable with a net income margin of -15.51%. Recent news highlights accelerated growth and AI-driven product enhancements, such as new agentic AI capabilities announced on April 23, 2026.
The investment outlook is positive, driven by analyst consensus with a $34.78 price target and 96% buy ratings. Key opportunities include sustained revenue acceleration and AI adoption, while risks involve persistent losses and competitive pressures in the customer engagement software sector. Cash flow improvements in 2025 provide a foundation, but profitability remains a critical hurdle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →
